| CAS NO: | 491-70-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| Molecular Weight (MW) | 286.24 |
|---|---|
| Formula | C15H10O6 |
| CAS No. | 491-70-3 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 57 mg/mL (199.1 mM) |
| Water:<1 mg/mL | |
| Ethanol: 3 mg/mL (10.5 mM) | |
| Other info | Chemical Name: 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone InChi Key: IQPNAANSBPBGFQ-UHFFFAOYSA-N InChi Code: InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H SMILES Code: O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13 |
| Synonyms | Flacitran; Luteoline; Luteolol; BRN-0292084; BCyanidenon 1470; Digitoflavone; Salifazide; Luteolin; BRN0292084; RN 0292084; C.I. 75590; C.I. Natural Yellow 2; CCRIS 3790; |
| In Vitro | In vitro activity: Luteolin is a flavonoid found in Terminalia chebula, which is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Ki of 15.0 μM, 6.4 μM, 13.9 μM, 11.1 μM and 9.5 μM, respectively. Luteolin inhibits LPS-stimulated TNF-alpha production with an IC50 of less than 1 μM. Luteolin inhibites LPS-induced phosphorylation of Akt as well as IkappaBalpha. Cell Assay: Luteolin (0-160 μM; 24 hours; NCI-H460 cells) treatment inhibits the viability of NCI-H460 cells in a concentration-dependent manner. Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment causes an accumulation of cells in the S phase. Luteolin (320-580 μM; 48 hours; NCI-H460 cells) treatment induces apoptosis. |
|---|---|
| In Vivo | Luteolin (10-100 mg/kg; oral gavage; daily; for 12 weeks; adult male Wistar rats) has an antioxidant effect and can also protect against non-alcoholic steatohepatitis through targeting the pro-inflammatory IL-1 and Il-18 pathways in rats with a high carbohydrate/high fat diet |
| Animal model | Male Wistar rats |
| Formulation & Dosage | 10-100 mg/kg; oral gavage |
| References | Eur J Pharmacol. 2010 Feb 10;627(1-3):269-75; J Pharmacol Exp Ther. 2001 Jan;296(1):181-7. |
m.cnreagent.com